mechanism of glp 1 receptor agonist Frontiers mechanism of action of glp

Description

NICE guidance (NG28) recommends considering GLP-1 receptor agonists for adults with type 2 diabetes when glycaemic targets are not achieved with other therapies, particularly in those with established cardiovascular disease or at high cardiovascular risk

Research-grade peptides sold by chemical suppliers operate under different regulatory frameworks than compounded pharmaceuticals dispensed by licensed pharmacies with prescriptions

The first oral (pill) form of a GLP-1 (semaglutide, brand name Wegovy) became available in January 2026

Adult patients with T2DM treated by metformin, thiazolidinediones/rosiglitazone or both without adequate glycaemic control after 3 months were enrolled in SUSTAIN 2 trial to explore the comparative effectiveness of semaglutide against sitagliptin